2
At A Glance We serve customers in a broad range of research, clinical, and applied markets, including: Who we serve Who we are Quick facts Francis deSouza President & CEO $2.75 billion (2017) Annual revenue 1998 Year founded ~7,000+ Number of employees San Diego, California, USA Headquarters Oncology Reproductive health Molecular & cell biology Agriculture We enable the adoption of genomic solutions in settings such as: Universities and academic research centers Genome centers Hospitals Government agencies Pharmaceutical companies Biotechnology companies Consumer genetics companies As a global leader in DNA sequencing and microarray-based solutions, we are dedicated to improving human health by unlocking the power of the genome. Our technology is responsible for generating more than 90% of the world’s sequencing data. 1 Genetic disease Microbiology Where we operate United States San Diego (Headquarters) Carroll Park Foster City Madison Brazil São Paulo United Kingdom Chesterford Fulbourn Cambridge France Évry Netherlands Eindhoven China Beijing Shanghai Japan Tokyo Osaka Singapore Australia Melbourne Korea Seoul

At A Glance - etp.tst-web.illumina.com · At A Glance We serve customers in a broad range of research, clinical, and applied markets, including: Who we serve Who we are Quick facts

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: At A Glance - etp.tst-web.illumina.com · At A Glance We serve customers in a broad range of research, clinical, and applied markets, including: Who we serve Who we are Quick facts

At A Glance

We serve customers in a broad range of research, clinical, and applied markets, including:

Who we serve

Who we are

Quick facts

Francis deSouzaPresident & CEO

$2.75 billion (2017)Annual revenue

1998Year founded

~7,000+Number of employees

San Diego, California, USAHeadquarters

OncologyReproductive

healthMolecular

& cell biologyAgriculture

We enable the adoption of genomic solutions in settings such as:

Universities and academic

research centers

Genome centers Hospitals

Government agencies

Pharmaceutical companies

Biotechnology companies

Consumer genetics

companies

As a global leader in DNA sequencing and microarray-based solutions, we are dedicated to improving human health by unlocking the power of the genome. Our technology is responsible for generating more than 90% of the world’s sequencing data.1

Genetic disease Microbiology

Where we operate

United StatesSan Diego (Headquarters)Carroll Park

Foster City

Madison

BrazilSão Paulo

United KingdomChesterford FulbournCambridge

FranceÉvry

NetherlandsEindhoven

ChinaBeijing

Shanghai

JapanTokyo

Osaka

Singapore

AustraliaMelbourne

Korea Seoul

Page 2: At A Glance - etp.tst-web.illumina.com · At A Glance We serve customers in a broad range of research, clinical, and applied markets, including: Who we serve Who we are Quick facts

For Research Use Only. Not for use in diagnostic procedures.

References1. Data calculations on �le. Illumina, Inc., 20172. Wetterstrand KA. DNA Sequencing Costs: Data from the NHGRI Genome Sequencing Program (GSP). Available at: www.genome.gov/sequencingcosts3. Illumina, Inc. HiSeq X™ Ten: $1,000 Genome and Extreme Throughput for Population-Scale Sequencing.

Available at: https://www.illumina.com/documents/products/datasheets/datasheet-hiseq-x-ten.pdf

© 2018 Illumina, Inc. All rights reserved. PUB 070-2017-022 QB 5893

Making breakthroughs possibleIllumina has developed one of the world’s most comprehensive genomics portfolio of integrated systems, consumables, and analysis tools. With each technological breakthrough, we help scientists better understand genetic variation at all levels of complexity.

$100 million2

$1,0003

2001

2017

Cost of sequencing, per human whole genome

Since 2001, the cost of DNA sequencing has dropped more than 100,000x from $100 million per human genome to $1,000 today. Discoveries that were unimaginable a few years ago are now becoming routine.

A recognized leader

World’s Most Innovative Companies List

Forbes 2014 (#36)Forbes 2015 (#35)Forbes 2016 (#24)Forbes 2017 (#18)

10 Breakthrough Technologies 2013

MIT Technology Review 2013

Top 50 Disruptive Companies MIT Technology

Review 2010, 2013

Fastest-Growing Tech Companies Forbes 2007, 2009, 2010

Fortune 2016

50 Smartest CompaniesMIT Technology Review

2014 (#1), 2015 (#3), 2016 (#3), 2017 (#22)

10 Most InnovativeBiotech Companies

Fast Company 2016, 2017

Sequencing systems

Array scanners

iScan™ System

Genotyping, CNV analysis, DNA methylation, and gene expression pro�ling.

HiSeq X™ Ten

High-throughput for population-scalewhole-genome sequencing.

HiSeq™ 4000

Production-scale instruments for genome sequencing, exome sequencing, and transcriptome sequencing.

NextSeq™ 550

Desktop sequencers for genome sequencing, exome sequencing, transcriptome sequencing and cytogenomic array scanning. Series includes NextSeq 550 and NextSeq 550Dx platforms.*

MiSeq™

Desktop sequencer for targeted and small-genome sequencing. Series includes MiSeq, MiSeqDx® platforms.†

MiniSeq™

Desktop sequencer for targeted DNA and targeted RNA sequencing.

NovaSeq™ 6000

High-throughput for any species, application, or scale of sequencing project.

iSeq™

Benchtop sequencer for targeted gene sequencing, direct amplicon sequencing, and small-genome sequencing.

*NextSeq 550Dx is FDA-regulated and CE-marked for in vitro diagnostic use.†MiSeqDx is a 510(k) cleared, CE-marked instrument for in vitro diagnostic use. MiSeq FGx is for forensic genomics applications.